Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919782 | 0.77 | TP53 (0.41) | TSHRTP53 | |
| SCHEMBL25624977 | 0.77 | TSHR (0.43) | TSHRTP53GRIK1GRIK2CYP2C9 | |
| SCHEMBL25624972 | 0.77 | TSHR (0.43) | TSHRTP53GRIK1GRIK2CYP2C9 | |
| SCHEMBL6919784 | 0.77 | TP53 (0.41) | TSHRTP53 | |
| SCHEMBL28362973 | 0.75 | SLC7A5 (0.44) | TP53GRIK1GRIK2 | |
| SCHEMBL19154903 | 0.75 | SLC7A5 (0.44) | TP53GRIK1GRIK2 | |
| SCHEMBL21901973 | 0.75 | SLC7A5 (0.44) | TP53GRIK1GRIK2 | |
| SCHEMBL18153964 | 0.74 | TSHR (0.45) | TSHRTP53CYP2C9PDE4ANFKB1 | |
| SCHEMBL17831093 | 0.74 | TSHR (0.45) | TSHRTP53CYP2C9PDE4A | |
| SCHEMBL18153965 | 0.74 | TSHR (0.45) | TSHRTP53CYP2C9PDE4ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680042-B2 | Compounds, reagents, and uses thereof | METABOLON, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20200231541-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680042-B2 | Compounds, reagents, and uses thereof | REN, ATP6V1B1, PKD1 | TSHR 2690/4885TP53 4554/4885GRIK1 2381/4885 |
| US-20200231541-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | REN, ATP6V1B1, PKD1 | TSHR 2690/4885TP53 4554/4885GRIK1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.